(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi
about
Pharmacokinetic and pharmacodynamic evaluation of linagliptin for the treatment of type 2 diabetes mellitus, with consideration of Asian patient populationsRole of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantationThe clinical application of linagliptin in AsiansAntidiabetic treatment with gliptins: focus on cardiovascular effects and outcomesThe Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including AtherosclerosisDPP-4 inhibition and islet functionLinagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesityInvestigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injuryThe dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivoPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemSafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese ratClinical pharmacokinetics and pharmacodynamics of linagliptin.The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.A DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in mice.Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts.Administration of pioglitazone alone or with alogliptin delays diabetes onset in UCD-T2DM rats.Efficacy and safety of linagliptin (tradjenta) in adults with type-2 diabetes mellitus.Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus.Pharmacokinetics of linagliptin in subjects with hepatic impairmentLinagliptin Ameliorates Methylglyoxal-Induced Peritoneal Fibrosis in MiceComparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital StudyThe DPP4 Inhibitor Linagliptin Protects from Experimental Diabetic RetinopathySensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats.Suppression of food intake by glucagon-like peptide-1 receptor agonists: relative potencies and role of dipeptidyl peptidase-4Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetesLinagliptin: A thorough Characterization beyond Its Clinical EfficacySafety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series.Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetesDPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal CellsLinagliptin as add-on therapy to insulin for patients with type 2 diabetesOL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.
P2860
Q26749524-D8B81BB9-DDB8-4043-AD99-E2216773092BQ26778329-E83DBE3D-B5FA-4DFB-B5E1-E2A776AFFF9CQ26781942-C5C96774-5AC5-49B7-B2E8-EBB4DEA42738Q26785454-77B2299D-1D57-4389-9739-F7C75A64A3F0Q26795473-7CF66E6F-5DF9-4B87-9266-4C5A8E5EEFEAQ27028127-8BB064F9-F2D7-418F-B59D-792C8D7C27AAQ28728101-25850BB8-675A-4756-9723-3C892EA027E0Q30426407-E62F2F5F-513D-491D-B0A1-5533EAF163D9Q33763289-9C3AFFF0-88C2-4E2D-B5E2-0E406645CE56Q33826729-14A8ED89-E15B-4745-B850-2AA9EA2F0862Q33849176-87229A57-02FC-48E3-A106-7A33AA032DDBQ34062829-EA03F4AB-93A1-4E22-A019-5910F188B4D6Q34135837-0352D6C8-F4E2-49D8-B622-15BAAE02BAC2Q34219918-49CDBC11-7CDD-4CF5-9D54-ED44F8E53B85Q34270500-DAC6CC90-B2A1-436D-9A0B-3B1AC7FA53D8Q34638128-4BD6D794-D632-45C4-8EAB-BB83BEB0F5ADQ35120585-D13EB493-5C18-4373-8790-9F450DB3926BQ35175774-C9B83085-58BE-4307-A1F2-D42E7E2973D2Q35531314-3767A7F7-A148-4A4F-B640-C21846A56BBCQ35688028-8C4774CC-BC37-496E-8821-0796F16B33B6Q35752928-0EE14721-9C87-465E-9216-EAA6C660F7FDQ35800419-9166256D-04FB-40AE-847D-F7F56576DA8FQ36087961-83E69561-F74A-4C6E-869C-776C98AC24B0Q36101582-A549BE16-2CB8-4C0E-A195-E2B1DC373668Q36188856-8A2B420D-1DBB-4FAE-A49A-DE2A4E9EA4DCQ36220047-27401012-BAB0-4577-83D6-D104AA40FF6AQ36332490-062C6040-ABCE-438C-96F7-2E6F8B37AB38Q36439654-19D9F239-C529-4C99-8C54-BE19518D4A68Q36520758-205A4892-6BC5-4C83-86CE-C56A32FB7488Q36636639-E1065807-5C27-4AAD-9D56-EF6CD1E9006EQ36883337-3567CC5A-F260-4C7F-A324-CF27F2AF49C1Q37015654-419C989A-6ACA-408D-90E0-286BF4530A63Q37033531-0345AD6E-F280-4433-B353-DE3778FD0393Q37161909-93398688-253E-44B3-AD26-DE59B5A31C03Q37195882-E0CE292C-FC8C-41D3-B4D4-04FE2392965AQ37227407-5534F884-6AE5-457C-89B0-30666183E079Q37275631-F40DD66F-9481-466D-993B-4426A6F9C368Q37281205-EA0B9263-DC2B-4342-81FB-535B6BF46BDDQ37325663-85484531-DCF1-4903-AC9B-61405378CE56Q37346130-14FBA4C2-D7A7-4D02-9837-B3B8B4316F38
P2860
(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@en
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@nl
type
label
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@en
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@nl
prefLabel
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@en
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@nl
P2093
P356
P1476
(R)-8-(3-amino-piperidin-1-yl) ...... duration of action compared wi
@en
P2093
Elke Langkopf
Frank Himmelsbach
Leo Thomas
Matthias Eckhardt
Michael Mark
Moh Tadayyon
P304
P356
10.1124/JPET.107.135723
P407
P577
2008-01-25T00:00:00Z